blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3522914

EP3522914 - VASOCONSTRICTIVE AND ANTIBACTERIAL COMBINATION TREATMENT FOR ROSACEA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.01.2024
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  03.02.2023
FormerGrant of patent is intended
Status updated on  26.09.2022
FormerExamination is in progress
Status updated on  22.06.2020
FormerRequest for examination was made
Status updated on  12.07.2019
FormerThe international publication has been made
Status updated on  14.04.2018
Formerunknown
Status updated on  04.11.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Micreos Human Health B.V.
Bankaplein 2
2585 EV Den Haag / NL
[2019/33]
Inventor(s)01 / OFFERHAUS, Mark Leonard
Kiplaan 3
2566 SN Den Haag / NL
02 / HERPERS, Bjorn Lars
Heinsiuslaan 1
2012 PB Haarlem / NL
 [2019/33]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2019/33]
Application number, filing date17788134.905.10.2017
[2019/33]
WO2017EP75407
Priority number, dateWO2016EP7403607.10.2016         Original published format: PCT/EP2016/074036
[2019/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018065546
Date:12.04.2018
Language:EN
[2018/15]
Type: A1 Application with search report 
No.:EP3522914
Date:14.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 12.04.2018 takes the place of the publication of the European patent application.
[2019/33]
Type: B1 Patent specification 
No.:EP3522914
Date:08.03.2023
Language:EN
[2023/10]
Search report(s)International search report - published on:EP12.04.2018
ClassificationIPC:A61K38/47, A61K38/48, A61K31/415, A61K31/4174, A61K31/498, A61P9/14, A61K31/4164, A61K45/06, A61P9/00, A61P17/00, A61P31/04
[2022/37]
CPC:
A61K38/47 (EP,IL,KR,US); A61K31/498 (EP,IL,KR,US); A61K31/4164 (EP,IL,KR,US);
A61K31/4174 (EP,IL,KR,US); A61K38/4886 (EP,IL,KR,US); A61K45/06 (EP,IL,KR,US);
A61P17/00 (EP,KR); A61P31/04 (EP,US); A61P9/00 (EP,KR);
A61P9/14 (EP); C12Y302/01017 (EP,IL,KR,US); C12Y304/24075 (EP,IL,KR,US);
A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/4164, A61K2300/00 (EP,US);
A61K31/4174, A61K2300/00 (US,EP);
A61K31/498, A61K2300/00 (EP,US);
A61K38/47, A61K2300/00 (US,EP);
A61K38/4886, A61K2300/00 (US,EP)
(-)
Former IPC [2019/33]A61K38/47, A61K38/48, A61K31/415, A61K31/4174, A61K31/498, A61P9/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/33]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:BEHANDLUNG VON ROSACEA MIT EINER GEFÄSSVERENGENDEN UND ANTIBAKTERIELLEN KOMBINATION[2019/33]
English:VASOCONSTRICTIVE AND ANTIBACTERIAL COMBINATION TREATMENT FOR ROSACEA[2019/33]
French:POLYTHÉRAPIE VASOCONSTRICTRICE ET ANTIBACTÉRIENNE CONTRE LA ROSACÉE[2019/33]
Entry into regional phase29.04.2019National basic fee paid 
29.04.2019Designation fee(s) paid 
29.04.2019Examination fee paid 
Examination procedure29.04.2019Amendment by applicant (claims and/or description)
29.04.2019Examination requested  [2019/33]
29.04.2019Date on which the examining division has become responsible
25.06.2020Despatch of a communication from the examining division (Time limit: M06)
14.12.2020Reply to a communication from the examining division
17.05.2021Despatch of a communication from the examining division (Time limit: M04)
24.08.2021Reply to a communication from the examining division
27.09.2022Communication of intention to grant the patent
23.01.2023Fee for grant paid
23.01.2023Fee for publishing/printing paid
23.01.2023Receipt of the translation of the claim(s)
Opposition(s)11.12.2023No opposition filed within time limit [2024/07]
Fees paidRenewal fee
17.09.2019Renewal fee patent year 03
25.09.2020Renewal fee patent year 04
29.09.2021Renewal fee patent year 05
27.09.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY05.10.2017
HU05.10.2017
AT08.03.2023
BG08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
TR08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE05.10.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
[2026/04]
Former [2025/39]CY05.10.2017
HU05.10.2017
AT08.03.2023
BG08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE05.10.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
Former [2025/36]CY05.10.2017
AT08.03.2023
BG08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE05.10.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
Former [2024/51]AT08.03.2023
BG08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE05.10.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
Former [2024/46]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
IE05.10.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
Former [2024/36]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU05.10.2023
BE31.10.2023
CH31.10.2023
Former [2024/34]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU05.10.2023
CH31.10.2023
Former [2024/30]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU05.10.2023
Former [2024/28]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2024/26]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2024/10]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/50]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/49]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/48]AT08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/46]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/37]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/36]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
Former [2023/35]ES08.03.2023
HR08.03.2023
LT08.03.2023
RS08.03.2023
NO08.06.2023
Former [2023/34]ES08.03.2023
LT08.03.2023
RS08.03.2023
Former [2023/33]ES08.03.2023
LT08.03.2023
Cited inInternational search[XY] US2012082625  (GRAEBER MICHAEL et al.)
 [XY] US2002187136  (LOOMIS LAWRENCE et al.)
 [XY] US2014343067  (SCHERER WARREN J et al.)
 [YD] WO2015005787  (MICREOS HUMAN HEALTH BV et al.)
 [A]   ANONYMOUS: "DrugBank: Bacitracin (DB00626)", 1 October 2015 (2015-10-01), XP055256703, Retrieved from the Internet [retrieved on 20160309]
 [Y]   JASON EMER ET AL: "Update on the management of rosacea", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 April 2015 (2015-04-01), pages 159, XP055256706, DOI: 10.2147/CCID.S58940

DOI:   http://dx.doi.org/10.2147/CCID.S58940
 [Y]   ANONYMOUS: "Staphefekt(TM) by Micreos", 28 May 2015 (2015-05-28), XP055256709, Retrieved from the Internet [retrieved on 20160309]
Examination  SHANLER S D ET AL: "Successful treatment of the erythema and flushing of rosacea using a topically applied selective [alpha]1-adrenergic receptor agonist, oxymetazoline", ARCHIVES OF DERMATOLOGY, AMERICAN MEDICAL ASSOCIATION, US, vol. 143, no. 11, 1 November 2007 (2007-11-01), pages 1369 - 1371, XP008179313, ISSN: 0003-987X, DOI: 10.1001/ARCHDERM.143.11.1369

DOI:   http://dx.doi.org/10.1001/archderm.143.11.1369
by applicantEP5158880
 WO2015005787
   CULP; SCHEINFELD, PHARMACY AND THERAPEUTICS, vol. 34, no. l, 2009, pages 38 - 45
   LOESSNER ET AL., MOLECULAR MICROBIOLOGY, vol. 44, no. 2, 2002, pages 335 - 349
   "Computational Molecular Biology", 1988, OXFORD UNIVERSITY PRESS
   "Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS
   "Computer Analysis of Sequence Data", 1994, HUMANA PRESS
   HEINE, G.: "Sequence Analysis in Molecular Biology", 1987, ACADEMIC PRESS
   "Sequence Analysis Primer", 1991, M STOCKTON PRESS
   CARILLO, H.; LIPMAN, D., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073
   DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
   ALTSCHUL, S. F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   ALTSCHUL, S. ET AL.: "BLAST Manual", NCBI NLM NIH, pages: 20894
   ALTSCHUL, S. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
   HENTIKOFF; HENTIKOFF, PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 10915 - 10919
   KOZAK, J. BIOL. CHEM., vol. 266, 1991, pages 19867 - 19870
   TWO AM; WU W; GALLO RL ET AL.: "Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors", JAM ACAD DERMATOL, vol. 72, 2015, pages 749 - 58
   STEINHOFF M; SCHAUBER J; LEYDEN JJ: "New insights into rosacea pathophysiology: a review of recent findings", J AM ACAD DERMATOL, vol. 69, 2013, pages 15 - 26
   YAMASAKI K; KANADA K; MACLEOD DT ET AL.: "TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes", J INVEST DERMATOL, vol. 131, 2011, pages 688 - 97
   KOLLER B; MULLER-WIEFEL AS; RUPEC R ET AL.: "Chitin modulates innate immune responses of keratinocytes", PLOS ONE, vol. 6, 2011, pages e16594
   LACEY N; DELANEY S; KAVANAGH K ET AL.: "Mite-related bacterial antigens stimulate inflammatory cells in rosacea", BR J DERMATOL, vol. 157, 2007, pages 474 - 81, XP055078471, DOI: doi:10.1111/j.1365-2133.2007.08028.x

DOI:   http://dx.doi.org/10.1111/j.1365-2133.2007.08028.x
   BELKAID Y; SEGRE JA: "Dialogue between skin microbiota and immunity", SCIENCE, vol. 346, 2014, pages 954 - 9
   FOURNIER B; PHILPOTT DJ: "Recognition of Staphylococcus aureus by the innate immune system", CLIN MICROBIOL REV, vol. 18, 2005, pages 521 - 40
   CULP; SCHEINFELD: "Rosacea: A review", PHARMACY AND THERAPEUTICS, vol. 34, 2009, pages 38 - 45, XP002698045
   SHANLER, S; ONDO, AL: "Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha-adrenergic receptor agonist, oxymetazoline", ARCH DERMATOLOGY, vol. 143, 2007, pages 1369 - 1371, XP008179313, DOI: doi:10.1001/archderm.143.11.1369

DOI:   http://dx.doi.org/10.1001/archderm.143.11.1369
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.